Marc Nolte

This inventor holds 24 USPTO granted patents and 30 published patent applications, plus 14 CIPO patents and 22 EPO patents, primarily in Agrochemical Formulations. Top assignees: Csl Behring Gmbh, Basf Se Corporation, Csl Limited. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc Nolte. Retrieved from https://idiyas.com/inventor/marc-nolte

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 30)

% Patents Active = 91.7

CIPO Patents = 14 (Patent Applications = 5)

EPO Patents = 22 (Patent Applications = 46)

Average Co-Inventor Count = 6.0

ph-index = 5

Forward Citations = 59(Granted Patents)

Location History:

Mannheim, DE (2013 - 2017)
Lahntal, DE (2016 - 2017)
Michelbach, DE (2016 - 2018)
Limburgerhof, DE (2022)
Marburg, DE (2018 - 2024)

Company Filing History:

Julius-Maximilians-Universitaet Wuerzburg

patents

7. 1 out of 3,076

The General Hospital Corporation

Westfaelische Wilhelms-Universitaet Muenster

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Agrochemical Formulations

Factor XII Inhibitors

Neurotraumatic Disorder

Remote Ischemia-Reperfusion Injury

Pesticide Composition

Monoclonal Antibodies

Chronic Kidney Disease

Nucleic Acids

Portable Spray Device

Graft Polymers

Aqueous Composition

Arthropod Control

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12685309 - Agrochemical formulations (2026-07-21),

2. 12376586 - Microcapsules comprising cinmethyln in the core and a polyurea derived from diphenylmethane diisocyanate or an oligomer thereof (2025-08-05),

3. 12065481 - Therapy using a factor XII inhibitor in a neurotraumatic disorder (2024-08-20),

4. 11505619 - Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease (2022-11-22),

5. 11345759 - Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies (2022-05-31),

6. 11235343 - Portable spray device (2022-02-01),

7. 10973891 - Treatment and prevention of remote ischemia-reperfusion injury (2021-04-13),

8. 10513560 - Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies (2019-12-24),

9. 10286047 - Treatment and prevention of remote ischemia-reperfusion injury (2019-05-14),

10. 9987328 - Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces (2018-06-05),

11. 9957329 - Factor XII inhibitors for the treatment of neurological inflammatory disorders (2018-05-01),

12. 9856326 - Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies (2018-01-02),

13. 9856325 - Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies (2018-01-02),

14. 9832990 - Composition comprising an active substance and a polyalkyleneoxide vinylester graft polymer (2017-12-05),

15. 9814233 - Composition comprising a pesticide, a surfactant and an alkoxylate of 2-propyheptylamine (2017-11-14),

Title: The Innovative Mind of Marc Nolte

Introduction

Marc Nolte is a distinguished inventor based in Marburg, Germany, recognized for his significant contributions in the field of medical innovations. With a remarkable portfolio of 14 patents, Nolte has demonstrated a profound commitment to advancing therapeutic solutions that address critical health issues.

Latest Patents

Among Marc Nolte's most recent inventions is a patent centered on the use of a Factor XII (FXII) inhibitor in treating neurotraumatic disorders. This invention specifically targets traumatic brain injuries (TBI) and spinal cord injuries (SCI) by leveraging the efficacy of direct FXII inhibitors. Another notable patent involves the use of FXII inhibitors in the treatment and prevention of chronic kidney disease and renal fibrosis. This invention encompasses comprehensive methodologies to mitigate renal scarring and associated injuries, enhancing the quality of care for patients facing serious kidney conditions.

Career Highlights

Throughout his professional journey, Marc has worked with prominent companies in the pharmaceutical sector, including CSL Behring GmbH and CSL Limited. His experiences in these companies have facilitated the development of innovative therapies that positively impact patient outcomes and drive progress in medical research.

Collaborations

Marc Nolte has collaborated with esteemed colleagues such as Con Panousis and Veronika Rayzman. These partnerships have played a crucial role in advancing his research and bolstering the development of groundbreaking treatments within his field.

Conclusion

Marc Nolte stands out as a beacon of innovation in the realm of medical inventions. His rigorous research and dedication to improving health outcomes through inventive therapies reflect his status as a leading inventor in today’s healthcare landscape. His contributions promise to reshape how we approach the treatment of complex medical conditions and solidify his legacy within the medical community.

Profile summary based on public USPTO records.